Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium.

Original Source of Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium

Bloomberg is reporting that Genzyme has rejected Sanofi-Aventis’ offer for the company. Citing people familiar with the matter, the Wall Street Journal reported last Friday that the

FDA advisory panel members overwhelmingly rejected a plan to reduce the misuse and abuse of long-acting painkillers like OxyContin, saying they did not think it was strong enough to control the use of such prescription narcotics. Report

Original Source of FDA panel: Painkiller plan not strong enough

The FDA just gave Eisai a new weapon against generic competition for the company’s flagship Alzheimer’s

In the ongoing fight about sales rep overtime pay, chalk up a win for management. As BNet Pharma reports, reps at King Pharmaceuticals’ ( NYSE: KG ) Alpharma unit lost their bid to break out of the overtime exemption. The judge’s ruling brings the number of overtime cases decided…

Sound the alarm on Lovenox–generic competition is coming. The Sanofi-Aventis

The FDA is looking to higher-ups for help sorting out a potential conflict of interest on the recent Avandia advisory panel. After news emerged last week that one panelist, endocrinologist David Capuzzi, had been paid to speak on behalf of a GlaxoSmithKline ( NYSE: GSK ) product, agency officials…

Neuromuscular diseases (NMDs) are chronic and so far incurable conditions that gradually affect patients’ muscles, leading to potentially severe disabilities. Biomedical researchers are busy looking for the diseases’ Achilles’ heel.

Original Source of Tracking down neuromuscular diseases

Sanofi-Aventis ( NYSE: SNY )

Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).

Original Source of Sandoz leads the way with first generic version of ‘gold standard’ anti-thrombotic Lovenox®